Reading view
Security of OpenClaw Agents: Fundamentals, Attacks, and Countermeasures
Adaptive Graph Refinement and Label Propagation with LLMs for Cost-Effective Entity Resolution
Towards generalizable seizure monitoring: EpiVLM for cross-environment detection and classification
npj Digital Medicine, Published online: 26 May 2026; doi:10.1038/s41746-026-02810-3
Towards generalizable seizure monitoring: EpiVLM for cross-environment detection and classificationFetal monitoring for high-risk pregnancies using a wearable ultrasound patch
Nature Biotechnology, Published online: 26 May 2026; doi:10.1038/s41587-026-03140-1
A wearable ultrasound device is optimized for continuous monitoring of pregnancies.Liver-specific <i>SIRT1</i> knockout-induced hyperglycemia promotes spontaneous lung adenocarcinomas through HSF1-MDM2
Oncogene, Published online: 24 May 2026; doi:10.1038/s41388-026-03826-5
Liver-specific SIRT1 knockout-induced hyperglycemia promotes spontaneous lung adenocarcinomas through HSF1-MDM2A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy
Evaluating large language models for simplifying non-English medical consent with clinician involvement
npj Digital Medicine, Published online: 01 April 2026; doi:10.1038/s41746-026-02591-9
Evaluating large language models for simplifying non-English medical consent with clinician involvementBridging the Know-Act Gap via Task-Level Autoregressive Reasoning
From Noisy Labels to Intrinsic Structure: A Geometric-Structural Dual-Guided Framework for Noise-Robust Medical Image Segmentation
A Review of the Role of Zeqi Decoction in the Treatment of Non-Small Cell Lung Cancer
J Multidiscip Healthc. 2026 Mar 11;19:584071. doi: 10.2147/JMDH.S584071. eCollection 2026.
ABSTRACT
Non-small cell lung cancer (NSCLC) is one of the malignant tumors with the highest incidence and mortality rates. Zeqi Decoction has the functions of "promoting diuresis and reducing swelling, resolving phlegm and dispersing nodules", embodying the unique approach of traditional Chinese medicine in treating lung cancer by "strengthening the body's resistance and eliminating pathogenic factors". Modern research shows that Zeqi Decoction exerts anti-NSCLC effects through multiple pathways and targets. In terms of the material basis of its efficacy, its active ingredients (such as diterpene esters and flavonoids contained in Zeqi) have the ability to directly inhibit the proliferation, invasion and migration of tumor cells and induce apoptosis. In terms of the mechanism of action, basic experiments have revealed that Zeqi Decoction can down-regulate the S100A9/STAT3 signaling pathway, inhibit the immunosuppressive activity of myelium-derived suppressor cells (MDSCs), reshape the tumor microenvironment, thereby enhancing the cytotoxic function of CD8⁺T cells, and can also regulate the EGFR/PI3K/Akt pathway to affect PD-L1 expression. Intervene in tumor immune escape; In terms of clinical transformation, the combination of Zexi Decoction with chemotherapy and targeted therapy can improve patients' symptoms such as cough and pleural effusion, prolong progression-free survival, and alleviate the toxic and side effects of Western medical treatment. In addition, Zexi Decoction also shows potential value in reversing drug resistance such as gemcitabine. At present, there are still problems such as the lack of standardized protocols and unclear molecular mechanisms in the research. In the future, it is necessary to combine new technologies such as network pharmacology and multi-omics analysis to deepen the research on the pharmacological material basis, dose-effect relationship and evidence-based medicine of Zeqi Decoction, so as to promote the clinical application and transformation of the combination of traditional Chinese and Western medicine in the treatment of NSCLC.
PMID:41847115 | PMC:PMC12991379 | DOI:10.2147/JMDH.S584071
Inhibition of ZBTB7B-mediated ADPGK transcription by NEDD4 impedes glycolysis and progression of lung adenocarcinoma
Oncogenesis, Published online: 11 March 2026; doi:10.1038/s41389-026-00605-5
Inhibition of ZBTB7B-mediated ADPGK transcription by NEDD4 impedes glycolysis and progression of lung adenocarcinoma